Aligos Therapeutics, Inc.
Business
Aligos Therapeutics is a clinical-stage biotechnology company developing novel small-molecule and oligonucleotide therapeutics for liver diseases and viral infections. The company's pipeline includes pevifoscorvir sodium (a capsid assembly modulator for chronic hepatitis B, in Phase 2), ALG-055009 (a thyroid hormone receptor beta agonist for MASH and obesity, in Phase 2a), and ALG-097558 (a ritonavir-free coronavirus protease inhibitor, in Phase 2). Aligos operates globally with development and commercialization rights to its candidates through exclusive licenses from Emory University and KU Leuven, and plans independent development in select indications while exploring partnerships for larger markets.
Summary from 10-K filed 2026-03-05
Financials
Consolidated Statement of Income
| Concept | Trend | FY 2025 2025-12-31 | FY 2024 2024-12-31 | FY 2023 2023-12-31 | FY 2022 2022-12-31 | FY 2021 2021-12-31 |
|---|---|---|---|---|---|---|
| Revenue from collaborations | 0 | 334,000 | 9 | 14 | 4 | |
| Revenue from customers | 2 | 4 | 6 | — | — | |
| Research and development | 69 | 70 | 73 | 85 | 104 | |
| General and administrative | 21 | 23 | 31 | 26 | 29 | |
| Total operating expenses | 90 | 93 | 104 | 111 | 133 | |
| Loss from operations | −88 | −89 | −88 | −98 | −128 | |
| Interest and other income, net | 4 | 4 | 3 | 2 | 132,000 | |
| Change in fair value of 2023 Common Warrants | 60 | −46 | −2 | — | — | |
| Loss before income tax | −24 | −131 | −87 | −96 | −128 | |
| Income tax provision | −314,000 | −331,000 | −795,000 | −106,000 | −143,000 | |
| Net loss | −24 | −131 | −88 | −96 | −128 | |
| Unrealized gain on available-for-sale securities | 22,000 | 9,000 | 96,000 | −57,000 | — | |
| Unrealized loss on pension plans | −5,000 | −103,000 | 48,000 | 6,000 | 749,000 | |
| Other comprehensive income (loss) | 17,000 | −94,000 | 144,000 | −51,000 | — | |
| Comprehensive loss | −24 | −131 | −88 | −96 | −128 | |
| Net loss per share, basic | −2.45 | −20.94 | −34.2 | −2.25 | — | |
| Net loss per share, diluted | −2.45 | −20.94 | −34.2 | −2.25 | — | |
| Weighted average shares of common stock, basic | 10 | 6 | 3 | 43 | — | |
| Weighted average shares of common stock, diluted | 10 | 6 | 3 | 43 | — |
Consolidated Balance Sheet
| Concept | Trend | FY 2025 2025-12-31 | FY 2024 2024-12-31 | FY 2023 2023-12-31 | FY 2022 2022-12-31 | FY 2021 2021-12-31 |
|---|---|---|---|---|---|---|
| Cash and cash equivalents | 18 | 37 | 136 | 81 | 187 | |
| Restricted cash | 100,000 | 100,000 | 100,000 | 100,000 | 200,000 | |
| Short-term investments | 60 | 20 | — | 44 | 4 | |
| Other current assets | 5 | 5 | 5 | 8 | 14 | |
| Total current assets | 83 | 62 | 141 | 134 | 204 | |
| Operating lease right-of-use assets | 3 | 5 | 7 | 8 | 9 | |
| Property and equipment, net | 2 | 2 | 3 | 5 | 6 | |
| Other assets | 715,000 | 627,000 | 625,000 | 634,000 | 866,000 | |
| Total assets | 89 | 70 | 152 | 147 | 235 | |
| Accounts payable | 4 | 3 | 3 | 5 | 3 | |
| Accrued liabilities | 14 | 16 | 17 | 16 | 25 | |
| Operating lease liabilities, current | 4 | 3 | 3 | 3 | 3 | |
| Finance lease liabilities, current | 145,000 | 36,000 | 10,000 | 108,000 | 138,000 | |
| Deferred revenue, current | 0 | 151,000 | 1 | — | — | |
| Total current liabilities | 21 | 22 | 24 | 33 | 39 | |
| Operating lease liabilities, net of current portion | 2 | 5 | 8 | 9 | 11 | |
| Finance lease liabilities, net of current portion | 0 | 122,000 | 231,000 | 230,000 | 261,000 | |
| 2023 Common Warrants liability | 12 | 72 | — | — | — | |
| Long term liability | 47,000 | 46,000 | 46,000 | — | 133,000 | |
| Total liabilities | 35 | 99 | 59 | 43 | 51 | |
| Commitments and contingencies (Note 12) | — | — | — | — | — | |
| Preferred Stock, $0.0001 par value; 10,000,000 shares authorized as of December 31, 2025 and December 31, 2024, respectively; no shares issued and outstanding as of December 31, 2025 and December 31, 2024, respectively. | 0 | 0 | — | — | — | |
| Common stock, $0.0001 par value; 115,800,000 shares and 20,800,000 shares authorized as of December 31, 2025 and December 31, 2024, respectively; 6,178,230 and 3,864,436 shares issued and outstanding as of December 31, 2025 and December 31, 2024, respectively | 9,000 | 8,000 | 7,000 | 4,000 | 4,000 | |
| Additional paid-in capital | 695 | 589 | 578 | 503 | 487 | |
| Accumulated deficit | −642 | −618 | −487 | −399 | −303 | |
| Accumulated other comprehensive income | 468,000 | 451,000 | 545,000 | 401,000 | 452,000 | |
| Total stockholders' equity (deficit) | 54 | −29 | 92 | 104 | 185 | |
| Total liabilities and stockholders' equity (deficit) | 89 | 70 | 152 | 147 | 235 |
Consolidated Statement of Cash Flows
| Concept | Trend | FY 2025 2025-12-31 | FY 2024 2024-12-31 | FY 2023 2023-12-31 | FY 2022 2022-12-31 | FY 2021 2021-12-31 |
|---|---|---|---|---|---|---|
| Accretion of discount on investments | −2 | −2 | −424,000 | −159,000 | 86,000 | |
| Non cash lease expense | 2 | 2 | 2 | 1 | 759,000 | |
| Change in fair value of 2023 Common Warrants | −60 | 46 | 2 | — | — | |
| Depreciation expense | 900,000 | 1 | 2 | 2 | 3 | |
| Stock-based compensation including ESPP | 5 | 8 | 13 | 15 | 13 | |
| Accounts payable | 1 | 54,000 | −2 | 2 | −313,000 | |
| Accrued liabilities | −2 | −1 | 918,000 | −9 | 10 | |
| Operating lease liabilities | −3 | −3 | −2 | −2 | −1 | |
| Deferred revenue | −151,000 | −1 | −8 | 3 | −4 | |
| Other assets | 96,000 | 216,000 | 2 | 6 | −8 | |
| Net cash and cash equivalents used in operating activities | −83 | −81 | −79 | −79 | −116 | |
| Maturities of short-term investments | 128 | 90 | 45 | 79 | 23 | |
| Purchase of short-term investments | −165 | −108 | −11,000 | −104 | −3 | |
| Purchases of property and equipment | −437,000 | −130,000 | — | — | — | |
| Net cash and cash equivalents used in investing activities | −38 | −18 | 45 | −26 | 3 | |
| Proceeds from issuance of common stock upon exercise of pre-funded warrants | — | 2,000 | — | — | — | |
| Proceeds from issuance of common stock, common warrants and pre-funded warrants in connection with PIPE offering, net of costs | 101 | — | — | — | — | |
| Payments on finance lease | −14,000 | −83,000 | −96,000 | −61,000 | −79,000 | |
| Proceeds from the ESPP purchase | 304,000 | 436,000 | 551,000 | 205,000 | — | |
| Net cash and cash equivalents provided by financing activities | 102 | 355,000 | 88 | 164,000 | 79 | |
| Net decrease in cash, cash equivalents, and restricted cash | −19 | −99 | 54 | −106 | −34 |
Filings
Material Events
Insiders
Institutional Holders
Frequently asked questions
What is Aligos Therapeutics, Inc.'s CIK number?
Aligos Therapeutics, Inc.'s SEC CIK number is 0001799448 (1799448). The CIK (Central Index Key) is the permanent identifier the SEC assigns to every EDGAR filer — unlike a ticker symbol, it never changes.
Where can I find Aligos Therapeutics, Inc.'s SEC filings?
All of Aligos Therapeutics, Inc.'s EDGAR filings — 10-K annual reports, 10-Q quarterly reports, 8-K material events, and insider transactions — are listed on this page, sourced live from SEC EDGAR.
When did Aligos Therapeutics, Inc. last report earnings?
Aligos Therapeutics, Inc. (ALGS) most recently filed an earnings 8-K with the SEC on May 7, 2026, furnishing its results under Item 2.02 (Results of Operations and Financial Condition). The earnings press release is attached to that filing (accession 0001171843-26-003156). This is Aligos Therapeutics, Inc.'s most recent earnings filing of record — not a forecast of its next earnings date.
What is Aligos Therapeutics, Inc.'s most recent earnings 8-K?
Aligos Therapeutics, Inc.'s latest earnings 8-K (Item 2.02) was filed May 7, 2026 under accession 0001171843-26-003156. It carries the quarterly or annual earnings press release — the earliest official, SEC-filed version of the results.
View Aligos Therapeutics, Inc.'s latest earnings 8-K →
Look up any company's CIK number →